REXLABAC Trademark

Trademark Overview

On Thursday, June 3, 2021, a trademark application was filed for REXLABAC with the United States Patent and Trademark Office. The USPTO has given the REXLABAC trademark a serial number of 90752761. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Tuesday, August 27, 2024. This trademark is owned by Azurity Pharmaceuticals, Inc.. The REXLABAC trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of spasticity resulting from multiple sclerosis, including relief of flexor spasms, concomitant pain, clonus, and muscular rigidity; pain relief medication
rexlabac

General Information

Serial Number90752761
Word MarkREXLABAC
Filing DateThursday, June 3, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateTuesday, August 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 1, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of spasticity resulting from multiple sclerosis, including relief of flexor spasms, concomitant pain, clonus, and muscular rigidity; pain relief medication

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 26, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAzurity Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWoburn, MA 01801
Party NameAzurity Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWoburn, MA 01801

Trademark Events

Event DateEvent Description
Wednesday, January 12, 2022NON-FINAL ACTION WRITTEN
Monday, June 7, 2021NEW APPLICATION ENTERED
Thursday, August 26, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 7, 2022ASSIGNED TO EXAMINER
Monday, January 24, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 12, 2022NON-FINAL ACTION E-MAILED
Wednesday, January 12, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 25, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 1, 2022PUBLISHED FOR OPPOSITION
Monday, January 24, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 26, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 9, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 1, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 26, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, August 31, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, August 31, 2022SOU EXTENSION 1 FILED
Wednesday, August 31, 2022SOU EXTENSION 1 GRANTED
Tuesday, August 29, 2023SOU EXTENSION 3 FILED
Friday, September 2, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 3, 2023SOU TEAS EXTENSION RECEIVED
Friday, March 3, 2023SOU EXTENSION 2 FILED
Friday, March 3, 2023SOU EXTENSION 2 GRANTED
Tuesday, March 7, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 29, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, August 29, 2023SOU EXTENSION 3 GRANTED
Thursday, August 31, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 4, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 27, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU EXTENSION 5 GRANTED
Tuesday, August 27, 2024SOU EXTENSION 5 FILED
Tuesday, March 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 4, 2024SOU EXTENSION 4 FILED
Monday, March 4, 2024SOU EXTENSION 4 GRANTED

Related Keywords

rexlabac pain relief concomitant spasms flexor clonus medication rigidity muscular including